Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Dendritic cells from patients with cancer are deficient in number and functional activity, leading to inadequate tumor immunosurveillance as a result of poor induction of T-cell antitumor responses. Loaded dendritic cell therapy is a vaccination strategy aimed at eliciting tumor antigen-specific, T-cell immune responses. Loaded dendritic cell therapy using prostatic acid phosphatase (APC8015; Provenge, Dendreon Corp., Seattle, WA) as an immunogen has shown a survival benefit in patients with metastatic hormone-refractory prostate cancer in a randomized phase III trial. This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment.
Lin
Amy M
AM
Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA.
Hershberg
Robert M
RM
Small
Eric J
EJ
D000135:Acid Phosphatase; D000938:Antigen-Presenting Cells / Q000201:enzymology* / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D017027:Protein Tyrosine Phosphatases / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic
D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases